Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Jilin Province Xidian Pharmaceutical Sci-Tech Development Co., Ltd specializes in the production of pharmaceutical intermediates and fine chemicals, primarily serving the domestic Chinese market. The company's competitive position is bolstered by its high gross margin of 76.3% and low debt levels, allowing it to maintain operational flexibility despite recent revenue declines.
The company generates revenue primarily through the sale of pharmaceutical intermediates and fine chemicals to domestic pharmaceutical manufacturers. Its competitive advantages include a strong focus on R&D, enabling the development of high-margin products, and a robust supply chain that minimizes production costs.
Changes in domestic pharmaceutical demand driven by healthcare policies
Fluctuations in raw material costs impacting gross margins
Regulatory changes affecting the pharmaceutical industry
Technological advancements in production processes
Regulatory changes that could impact product approvals and market access
Technological disruption from new production methods or alternative therapies
Increased competition from domestic and international pharmaceutical manufacturers
Potential for price erosion in key product segments
Low return on equity (2.5%) indicating potential inefficiencies in capital utilization
Negative free cash flow could limit future investment opportunities
moderate - The company's performance is linked to the overall health of the pharmaceutical sector, which is influenced by GDP growth and consumer spending on healthcare.
Interest rates affect the company's financing costs, although its low debt levels mitigate this risk. Higher rates could also dampen consumer spending on healthcare, indirectly impacting demand.
minimal - The company operates with a low debt-to-equity ratio of 0.04, reducing its reliance on credit markets.
value - Investors may be drawn to the company's low debt levels and high gross margins, despite recent revenue declines.
moderate - The stock has shown a historical volatility consistent with the chemicals sector, but recent performance suggests increased uncertainty.
